| Members |
targetComponentId |
| Hormone radioassay - thalamus &/or hypothalamus |
Hypothalamus hormone radioassay |
| Hormone radioassay - thalamus &/or hypothalamus |
Hormone radioassay - thalamus/hypothalamus (procedure) |
| Hormone radioassay - thalamus &/or hypothalamus |
Thalamus hormone radioassay |
| Hormone radioassay - thalamus &/or hypothalamus |
Hormone radioassay - thalamus/hypothalamus (procedure) |
| Hormone replace admin: [monitoring] or [clinic] |
Hormone replacement monitoring status |
| Hormone replace admin: [monitoring] or [clinic] |
Hormone replacement monitoring status |
| Hormone replacement therapy (& [prophylaxis] or [implant]) |
Hormone replacement therapy (procedure) |
| Hormone, synthetic hormone substitute or hormone antagonist |
Drug or medicament (substance) |
| Hormone, synthetic hormone substitute or hormone antagonist |
Hormone |
| Hormone, synthetic hormone substitute or hormone antagonist adverse reaction |
Adverse reaction to hormone |
| Hormonema species |
Hormonema |
| Hormones and their metabolites and precursors |
Drug or medicament (substance) |
| Hormones and their metabolites and precursors |
Hormone |
| Hormones, synthetic substitutes and antagonist overdose |
Overdose |
| Horn viper |
Vipera ammodytes (organism) |
| Horn viper |
Crotalus cerastes |
| Hornbeam pollen allergen |
Hornbeam pollen |
| Horned lark |
Eremophila alpestris (organism) |
| Horned lark |
Genus Eremophila (organism) |
| Horner's syndrome pupil |
Horner syndrome |
| Horner's syndrome pupil |
Horner syndrome |
| Hornet |
Dolichovespula maculata (organism) |
| Hornet |
European hornet |
| Horse |
Family Equidae (organism) |
| Horse |
Equus caballus (organism) |
| Horse |
Genus Equus (organism) |
| Horse fly |
Genus Tabanus (organism) |
| Horse fly |
Family Tabanidae (organism) |
| Hospital (& [ward]) orderly |
Hospital orderly |
| Hospital (& [ward]) orderly |
Hospital ward orderly |
| Hospital (& [ward]) orderly |
Hospital orderly |
| Hospital (& [ward]) orderly |
Hospital ward orderly |
| Hospital AND/OR institution |
Hospital |
| Hospital AND/OR institution |
Site of care |
| Hospital admission, for laboratory work-up, radiography, etc. |
Hospital admission |
| Hospital admission, type unclassified, explain by report |
Hospital admission |
| Hospital associated methicillin resistant Staphylococcus aureus |
Methicillin resistant Staphylococcus aureus |
| Hospital patient (& [inpatient]) |
Hospital patient |
| Hospital-based outpatient immunology clinic |
Hospital-based outpatient immunology clinic |
| Hospital-based outpatient immunology clinic |
Hospital-based outpatient allergy clinic |
| Hot balloon destruction |
Destructive procedure |
| Hot pack treatment |
Thermotherapy with hot packs (procedure) |
| Hot pack treatment |
Hydrotherapy with hot packs or compresses |
| Hot/cold therapy pack, reusable |
Hot/Cold therapy pack |
| Hot/cold therapy pack, single-use |
Hot/Cold therapy pack |
| House dust allergen |
House dust |
| House husband |
House husband (person) |
| House husband |
House husband (person) |
| House trailer, device (physical object) |
Mobile home |
| House trailer, device (physical object) |
Travel trailer recreational vehicle (physical object) |
| Housing &/or planning inspector |
Planning inspector |
| Housing &/or planning inspector |
Planning inspector |
| Housing &/or planning inspector |
Housing inspector |
| Housing &/or planning inspector |
Housing inspector |
| Housing &/or planning inspector |
Housing/planning inspector |
| Housing - awaiting action |
Finding relating to awaiting housing or re-housing |
| Housing very unsatisfactory |
Housing unsatisfactory (finding) |
| Human T-cell lymphotropic virus 1-associated myelopathy-tropical spastic paraparesis |
Myelopathy caused by Human T-lymphotropic virus 1 (disorder) |
| Human T-lymphotrophic virus recombinant glycoprotein 21 antibody |
Antibody to Human T-lymphotropic virus 2 recombinant glycoprotein 21 (substance) |
| Human T-lymphotrophic virus recombinant glycoprotein 21 antibody |
Antibody to Human T-lymphotropic virus 1 recombinant glycoprotein 21 (substance) |
| Human albumin solution |
Albumin human only product in parenteral dose form |
| Human alpha1 proteinase inhibitor |
Alpha1 proteinase inhibitor |
| Human alpha1 proteinase inhibitor 1000mg injection solution vial + diluent |
Human alpha1 proteinase inhibitor 1 g powder for solution for injection vial |
| Human anaplasmosis |
Human anaplasmosis caused by Anaplasma phagocytophilum |
| Human anaplasmosis |
Anaplasmosis |
| Human body structure |
Body structure |
| Human body structure |
Anatomical structure |
| Human bone for identification |
Human bone for identification (specimen) |
| Human cytomegalovirus group virus |
Subfamily Betaherpesvirinae (organism) |
| Human cytomegalovirus group virus |
Genus Cytomegalovirus (organism) |
| Human ehrlichiosis |
Human ehrlichiosis caused by Ehrlichia chaffeensis (disorder) |
| Human ehrlichiosis |
Human ehrlichiosis |
| Human hair structure |
Hair structure (body structure) |
| Human herpes cytomegalovirus group virus |
Genus Cytomegalovirus (organism) |
| Human herpes cytomegalovirus group virus |
Genus Roseolovirus (organism) |
| Human immunodeficiency virus (HIV) 1 p41 antibody assay |
Measurement of Human immunodeficiency virus 1 glycoprotein 41 antibody (procedure) |
| Human immunodeficiency virus (HIV) II infection category B2 |
Human immunodeficiency virus Centers for Disease Control and Prevention stage 2 (finding) |
| Human immunodeficiency virus (HIV) II infection category B2 |
Human immunodeficiency virus Centers for Disease Control and Prevention stage 3 (finding) |
| Human immunodeficiency virus (HIV) contact |
Exposure to Human immunodeficiency virus (event) |
| Human immunodeficiency virus (HIV) infection category B2 |
Human immunodeficiency virus Centers for Disease Control and Prevention stage 2 (finding) |
| Human immunodeficiency virus (HIV) infection category B2 |
Human immunodeficiency virus Centers for Disease Control and Prevention stage 3 (finding) |
| Human immunodeficiency virus 2 glycoprotein 36 antibody |
Antibody to Human immunodeficiency virus 2 glycoprotein 36 (substance) |
| Human immunodeficiency virus Centers for Disease Control and Prevention category A2 |
Human immunodeficiency virus Centers for Disease Control and Prevention stage 3 (finding) |
| Human immunodeficiency virus Centers for Disease Control and Prevention category A2 |
Human immunodeficiency virus Centers for Disease Control and Prevention stage 2 (finding) |
| Human immunodeficiency virus Centers for Disease Control and Prevention category A3 (acquired immunodeficiency syndrome) |
Human immunodeficiency virus Centers for Disease Control and Prevention stage 2 (finding) |
| Human immunodeficiency virus Centers for Disease Control and Prevention category A3 (acquired immunodeficiency syndrome) |
Human immunodeficiency virus Centers for Disease Control and Prevention stage 3 (finding) |
| Human immunodeficiency virus Centers for Disease Control and Prevention category B |
Human immunodeficiency virus Centers for Disease Control and Prevention stage 3 (finding) |
| Human immunodeficiency virus Centers for Disease Control and Prevention category B |
Human immunodeficiency virus Centers for Disease Control and Prevention stage 1 (finding) |
| Human immunodeficiency virus Centers for Disease Control and Prevention category B |
Human immunodeficiency virus Centers for Disease Control and Prevention stage 2 (finding) |
| Human immunodeficiency virus Centers for Disease Control and Prevention category B2 |
Human immunodeficiency virus Centers for Disease Control and Prevention stage 2 (finding) |
| Human immunodeficiency virus Centers for Disease Control and Prevention category B2 |
Human immunodeficiency virus Centers for Disease Control and Prevention stage 3 (finding) |
| Human immunodeficiency virus Centers for Disease Control and Prevention category B3 (acquired immunodeficiency syndrome) |
Human immunodeficiency virus Centers for Disease Control and Prevention stage 3 (finding) |
| Human immunodeficiency virus Centers for Disease Control and Prevention category B3 (acquired immunodeficiency syndrome) |
Human immunodeficiency virus Centers for Disease Control and Prevention stage 2 (finding) |
| Human immunodeficiency virus Centers for Disease Control and Prevention category C2 (acquired immunodeficiency syndrome) |
Human immunodeficiency virus Centers for Disease Control and Prevention stage 3 (finding) |
| Human immunodeficiency virus Centers for Disease Control and Prevention category C2 (acquired immunodeficiency syndrome) |
Human immunodeficiency virus Centers for Disease Control and Prevention stage 2 (finding) |
| Human immunodeficiency virus Centers for Disease Control and Prevention category C3 (acquired immunodeficiency syndrome) |
Human immunodeficiency virus Centers for Disease Control and Prevention stage 2 (finding) |
| Human immunodeficiency virus Centers for Disease Control and Prevention category C3 (acquired immunodeficiency syndrome) |
Human immunodeficiency virus Centers for Disease Control and Prevention stage 3 (finding) |
| Human immunodeficiency virus antibody/antigen, Duo |
HIV-1/HIV-2 antigen/antibody combination immunoassay |
| Human immunodeficiency virus disease resulting in Burkitt's lymphoma |
Burkitt lymphoma co-occurrent with human immunodeficiency virus infection (disorder) |
| Human immunodeficiency virus disease resulting in candidiasis |
Candidiasis |
| Human immunodeficiency virus disease resulting in candidiasis |
Symptomatic human immunodeficiency virus infection |